Selenium Yeast Study for Depression in Teenagers and Children
Tests selenium yeast against a placebo in young people with major depression.
Plain-language title generated from the registry record
Registry title: Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study
Key facts
- Where
- Chongqing, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 18 years old?
Source: NCT07203144, who can take part
Where in China
- The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Chongqing Medical University
- Trial code
- NCT07203144
- Record updated
- 31 August 2026
- Original description
The purpose of this study is to investigate the role and mechanisms of selenium in depression among children and adolescents, aiming to provide new insights for understanding the pathogenesis and treatment of depression in this population.Read full original descriptionShow less
Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study
The purpose of this study is to investigate the role and mechanisms of selenium in depression among children and adolescents, aiming to provide new insights for understanding the pathogenesis and treatment of depression in this population.
Inclusion: Aged 12-18 years; Diagnosed with major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), using the K-SADS-PL diagnostic tool; A score of ≥40 on the Children's Depression Rating Scale-Revised (CDRS-R); Adequate visual and auditory abilities to complete the study; Willingness to participate in the study with informed consent signed by both the participant and a legal guardian.
Exclusion: Patients currently taking medications contraindicated with the investigational drug or that may interfere with its efficacy; Those who have received modified electroconvulsive therapy (MECT) within the past 12 months; Patients with severe psychiatric disorders such as bipolar disorder, schizophrenia, bulimia nervosa, anorexia nervosa, or primary obsessive-compulsive disorder; Those with severe physical illnesses or other life-threatening conditions; patients in a current depressive episode with a clear suicidal plan or history of suicide attempt; Individuals with a history of substance or drug abuse; Those requiring immediate hospitalization for psychiatric disorders; Individuals allergic to selenium yeast protein, including those with allergic rhinitis, gastrointestinal sensitivity, allergic constitution, or autoimmune diseases such as Graves' disease or Hashimoto's thyroiditis; Patients with contraindications to magnetic resonance imaging (MRI); Left-handed individuals.